title: [The effect of cellex on cognitive and speech impairments in the acute stage of stroke].
abstract: OBJECTIVE
  To study the effect of cellex on the recovery of cognitive and speech functions in the acute stage of stroke.
  
  
  METHODS
  A multicenter comparative open clinical study of the efficacy and safety of cellex in treatment of patients with acute stroke was carried out in 6 clinical sites. The study involved 180 patients, including 147 (81.7%) with ischemic stroke and 33 (18.3%) with hemorrhagic stroke. Celex was introduced subcutaneously in dose 0.1 mg once a day during the first 10 days and from 21 to 27th days.
  
  
  CONCLUSIONS
  The rapid and complete recovery of neurological and cognitive functions was observed. The more marked dynamics was seen in patients with greater initial stroke severity and with large hemisphere lesions.
authors.affiliation: Kemerovo State Medical Academy; Research Institute for Complex Problems of Cardiovascular Diseases.
authors.forename: A V
authors.initials: AV
authors.lastname: Kovalenko
authors.affiliation: Kemerovo State Medical Academy; Regional Clinical Hospital for War Veterans.
authors.forename: M N
authors.initials: MN
authors.lastname: Safronova
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002540:Cerebral Cortex / Q000473:pathology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D013064:Speech Disorders / Q000188:drug therapy* / Q000209:etiology; D020521:Stroke / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D055815:Young Adult
chemical_list: D018696:Neuroprotective Agents; D010455:Peptides